Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS12 | P56730 | 9/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | F10 | P00742 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2733363 | 0.90 | PRSS12 (0.69) | PRSS12F10 | |
| SCHEMBL10246445 | 0.86 | MAPT (0.57) | PRSS12MAPTF10KDM4ENPC1 | |
| SCHEMBL2724682 | 0.82 | PRSS12 (0.82) | PRSS12MAPTKDM4ENPC1LMNA | |
| SCHEMBL15295591 | 0.79 | PRSS12 (0.80) | PRSS12F10 | |
| SCHEMBL2721359 | 0.78 | MAPT (0.61) | PRSS12MAPTF10 | |
| SCHEMBL2724932 | 0.78 | F10 (0.62) | PRSS12MAPTF10 | |
| SCHEMBL15295703 | 0.77 | PRSS12 (0.71) | PRSS12MAPTF10 | |
| SCHEMBL2721565 | 0.77 | PRSS12 (0.81) | PRSS12F10 | |
| SCHEMBL2724233 | 0.76 | PRSS12 (0.58) | PRSS12MAPTF10 | |
| SCHEMBL2724512 | 0.75 | F10 (0.64) | PRSS12MAPTF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| EP-2635559-A2 | NEUROTRYPSIN INHIBITORS | Neurotune AG (CH) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | PRSS12 5/4885MAPT 1060/4885F10 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.